Patritumab deruxtecan is a monoclonal antibody conjugated commercialized by Daiichi Sankyo, with a leading Pre-Registration program in Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 16 clinical trials, of which 2 were completed, 11 are ongoing, 2 are planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Patritumab deruxtecan’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Patritumab deruxtecan is expected to reach an annual total of $358 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Patritumab deruxtecan Overview
It was under development for the treatment of metastatic colorectal cancer, colon cancer, rectal adenocarcinoma, bladder cancer and skin cancer.
See Also:
Daiichi Sankyo Overview
Daiichi Sankyo is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.
For a complete picture of Patritumab deruxtecan’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.